Company news

Fate Therapeutics, Inc. news in 2019

Fate Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.

View company

Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting

December 9, 2019

Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy

December 7, 2019

Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs

December 6, 2019

Fate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

November 26, 2019

Fate Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

November 13, 2019

Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting

November 5, 2019

Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

November 4, 2019

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2019 Financial Results

October 28, 2019

Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies

September 29, 2019

Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

September 17, 2019

Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development

April 17, 2019

Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment

April 1, 2019

Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting

March 31, 2019

Decks in 2019